Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
TOP SEARCHES: OCT // Canaloplasty // AMD
In this issue
• Glaucoma diagnosis
• Diabetic retinopathy
• AMD clinical trial
• Controversial Congress
• Bevacizumab & AMD
• Diagnostics
Survey

What do you think about peeling the internal limiting membrane (ILM)?

Click here to vote


You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Pamela Brook, editor.

Click here to contact Neil Hanley, sales manager.
 
JANUARY 13, 2010
New study demonstrates potential for improving glaucoma diagnosis across Europe
According to Pfizer, newly published results from the European Optic Disc Assessment Trial (EODAT) reveal the accuracy of glaucoma diagnosis can be improved when patients' optic discs are assessed using common imaging devices, and suggests that post-graduate training courses in optic disc assessment would improve glaucoma care. More...
Can micronutrients help DR?
Researchers in The Netherlands have concluded that dietary intake or plasma levels of vitamins C and E and magnesium do not seem to be associated with diabetic retinopathy. More...
First ever sham-controlled study of radiation therapy for wet AMD
Oraya Therapeutics, Inc., has announced that enrolement is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD). The clinical trial is being conducted at seven European sites, and will include a minimum of 150 patients, with approximately one third of those receiving a sham exposure and the remainder receiving radiation dosing of either 16 or 24 Gray (GY). More...
Controversies in ophthalmology
Macular surgery, whether to peel or not to peel the internal limiting membrane, surgical management of various macular pathologies, the effect of catarct on diabetic retinopathy and controversial cases in retinal detachment are just some of the headlines from the Scientific Programme of the World Congress on Controversies in Ophthalmology, which takes place in March in Prague. More...
A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: The VIA study
Combination bevacizumab and 25–J/cm2 or 12–J/cm2 PDT significantly reduced the number of bevacizumab treatments required over six months. This study aimed at examining number of treatments, but not visual acuities. However, visual acuities responded favourably in all three groups. More...
BluePeak swirls online to new microsite
Heidelberg Engineering has launched an informative microsite about BluePeak blue laser autofluorescence. More...
Imaging & Diganostics
Blue Laser Autofluorescence
The fusion of imaging technology for today and tomorrow to assess your patients’ retinal health. Read more…

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.

To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail at Advanstar Communications, Advanstar House, Park West, Sealand Road, Chester, CH1 4RN, UK.